Atrial natriuretic peptide augments the variability of sympathetic nerve activity in human heart failure

Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial nat...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of hypertension Ročník 19; číslo 3 Pt 2; s. 619
Hlavní autoři:	Kubo, T, Ando, S, Picton, P, Atchison, D J, Notarius, C F, Pollard, M J, Abramson, B L, Floras, J S
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.03.2001
Témata:	Adult Angiotensin-Converting Enzyme Inhibitors - therapeutic use Atrial Natriuretic Factor - pharmacology Cardiac Output, Low - physiopathology Cardiomyopathy, Dilated - drug therapy Cardiomyopathy, Dilated - physiopathology Heart Rate - drug effects Humans Male Middle Aged Nitroglycerin - therapeutic use Sympathetic Nervous System - drug effects Sympathetic Nervous System - physiopathology Vasodilator Agents - therapeutic use
ISSN:	0263-6352
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Activation of the sympathetic nervous system, decreased heart rate variability (HRV), and loss of modulation of muscle sympathetic nerve activity (MSNA) within the low frequency (LF, 0.05-0.15 Hz) range are three adverse features of advanced congestive heart failure (CHF). In healthy men, atrial natriuretic peptide (ANP) infusion attenuates reflex increases in MSNA and reduces LF components of HRV spectral power. Sympathoinhibitory actions have also been documented in CHF, but effects on the variability of MSNA and HRV have not been described. Heart rate and MSNA were recorded in 10 men (aged 39 +/- 3 years, mean +/- SE) with dilated cardiomyopathy (mean EF 20 +/- 4%) treated with angiotensin converting enzyme (ACE) inhibitors. Subjects received i.v. ANP (50 microg bolus then 50 ng/kg/min) and nitroglycerin (NTG, 8 mg/min) as a hemodynamic control. Signals at baseline, and 13-20 min into each infusion were submitted to spectral analysis. ANP had no effect on HRV, but increased MSNA LF (from 7.9 +/- 1.5 to 12.1 +/- 2.6 U2; P< 0.02) and total spectral power (from 47.9 +/- 5.4 to 61.9 +/- 6.8 U2; P < 0.05). NTG had no effect on the variability of MSNA or HRV. In CHF patients receiving ACE inhibitors, ANP (i) does not suppress HRV and (ii) enhances the modulation of MSNA, particularly within the LF range. This latter action is not observed with NTG. These findings suggest beneficial actions of exogenous ANP on neurogenic circulatory control.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0263-6352
DOI:	10.1097/00004872-200103001-00015